Clinical Trials Logo

Metastatic Malignant Neoplasm clinical trials

View clinical trials related to Metastatic Malignant Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06240728 Recruiting - Clinical trials for Metastatic Malignant Neoplasm

A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting HHLA2 (B7-H7) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable in participants whose cancers are known to express HHLA2 (B7-H7).The main questions it aims to answer are: - what is an appropriate dose to be given to participants? - are the side effects of treatment manageable? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

NCT ID: NCT05958199 Recruiting - Clinical trials for Metastatic Malignant Neoplasm

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Start date: July 21, 2023
Phase: Phase 1
Study type: Interventional

NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are: - what is an appropriate dose to be given to patients? - are the side effects of treatment manageable? Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.

NCT ID: NCT04068649 Recruiting - Clinical trials for Metastatic Malignant Neoplasm

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Start date: November 18, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.